Organogenesis Faces Setback as Knee Osteoarthritis Therapy Fails Clinical Trial Endpoint

Organogenesis has encountered a significant setback as its knee osteoarthritis therapy failed to meet the primary endpoint in a recent clinical trial. This failure has led to a drop in the company's stock price and raised concerns about the treatment's effectiveness, potentially affecting investor confidence and future developments in osteoarthritis therapies.